A Phase 2 clinical trial of GDC-0310 for the treatment of pain

Trial Profile

A Phase 2 clinical trial of GDC-0310 for the treatment of pain

Planning
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs GDC 0310 (Primary)
  • Indications Pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Nov 2017 According to a Xenon Pharmaceuticals media release, based on the data from ongoing pre-clinical toxicology studies the company has decided to postpone the initiation of this trial. Future development will be updated once the pre-clinical studies are completed and the final results are analyzed.
    • 03 Aug 2017 According to a Xenon Pharmaceuticals media release, the company plans to initiate this study in the first quarter of 2018.
    • 11 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top